02 December 2021 | Thursday | News
- The HSA authorization of the Cue COVID-19 Test is for home use in both symptomatic and asymptomatic users, ages 2 years and up
- Cue Health has partnered with Omnicell Pte Ltd to immediately begin supplying the Cue COVID-19 Test in Singapore
Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore. Cue's partnership with Omnicell Pte Ltd allows Cue to immediately begin supporting public sector use of the Cue COVID-19 Test.
"We are excited to bring Cue's digitally connected, in-home molecular diagnostics platform to Singaporean stakeholders and help provide immediate access to critical health information. With Cue, users will be able to make faster and more informed healthcare decisions at a time when it's needed most," said Ayub Khattak, Co-Founder and CEO of Cue. "Singapore as a country has been a thought leader in adopting innovative healthcare technologies at scale and has been a leading example for other APAC countries in the region. Cue's HSA authorization sets the foundation for broad application of the Cue platform in Singapore."
Omnicell Pte Ltd Regional Account Director Yoco Ting commented, "Testing remains an important component in Singapore's overall strategy for managing COVID-19. With the recent authorization of the Cue COVID-19 Test via the Pandemic Special Access Route, Omnicell is excited to bring forth into Singapore the technological advancement from Cue and further simplify the COVID-19 testing process by now combining the speed of rapid antigen tests with the lab-quality accuracy of PCR tests. We will continue to work closely with local authorities and Cue to further the effort in controlling COVID-19 in Singapore."
As the maker of the first and only natively digital molecular diagnostics solution available in Singapore, Cue intends to explore both public and private sector partnerships that Cue believes will further enable the complete utilization of the Cue Health Monitoring System for not only the Cue COVID-19 Test, but also Cue's future test menu and other offerings.
Last month, Cue launched its direct-to-consumer (DTC) virtual health platform in the United States, making Cue's first-of-its-kind molecular COVID-19 test available through Cue's new eCommerce site and in-app shop. Cue's new membership offering — Cue+™ — offers members 24/7 on-demand access to board certified physicians, e-prescription services, CDC-compliant test results for travel through in-app video proctoring, and same-day delivery of Cue products in a number of major markets.